PureTech Health plc - American Depositary Shares (PRTC)
PRTC moved a median of 0.00% 30 minutes after news, and 0.00% by the close. How PRTC actually reacts to news — the realized, point-in-time move the market made, measured across 385 labeled events over the last three years with zero look-ahead.
PRTC’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 29% | 65 |
| 30-min | 0.00% | 45% | 106 |
| 60-min | 0.00% | 42% | 147 |
| to close | 0.00% | 31% | 319 |
| Middle 50% of PRTC reactions | -1.08% to +0.79% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 385 |
Half of all PureTech Health plc - American Depositary Shares news events land between -1.08% and +0.79% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when PRTC moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to PRTC's baseline. Nothing else.
Recent PRTC events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 15F-12B PureTech Health plc | SEC filing · Form 15F-12B | SEC EDGAR | — | — | |
| PureTech to Showcase Deupirfenidone Program at the American Thoracic Society International Conference | Press release | Business Wire | +0.00% | +0.57% | |
| PureTech Announces Annual Results for Year Ended December 31, 2025 | Press release | Business Wire | -0.11% | -1.97% | |
| PureTech Announces Intention to Voluntarily Delist American Depositary Shares from Nasdaq and Concentrate Trading on the London Stock Exchange | Press release | Business Wire | -0.11% | -1.97% | |
| PureTech Founded Entity Seaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of Directors | Press release | Business Wire | -1.61% | -0.23% | |
| PureTech Reports Positive Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory (R/R) High-Risk (HR) Myelodysplastic Syndrome (MDS) and R/R Acute Myeloid Leukemia (AML) | Press release | Business Wire | — | -2.51% | |
| PureTech Health: Notice of Results | Press release | Business Wire | -0.17% | -0.70% | |
| PureTech Announces Publication of Phase 2b ELEVATE IPF Trial Results in The American Journal of Respiratory and Critical Care Medicine | Press release | Business Wire | +0.00% | +2.10% | |
| PureTech Founded Entity Seaport Therapeutics Announces Positive Proof of Concept Topline Results from Ongoing Phase 1 Trial of GlyphAgo™ in Healthy Volunteers | Press release | Business Wire | +0.00% | +2.10% | |
| PureTech Founded Entity Seaport Therapeutics Announces Publication in Science Translational Medicine Featuring GlyphAllo™ (SPT-300) as the First Triglyceride-Mimetic Prodrug to Achieve Therapeutically Relevant Drug Levels in Humans | Press release | Business Wire | — | +0.00% | |
| PureTech to Present at the Leerink Partners Global Healthcare Conference | Press release | Business Wire | — | +0.52% | |
| PureTech Announces Orphan Drug Designations Granted by the U.S. Food and Drug Administration and European Commission for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis | Press release | Business Wire | +0.95% | +0.01% | |
| PureTech to Present at 44th Annual J.P. Morgan Healthcare Conference | Press release | Business Wire | — | -1.80% | |
| Form 6-K PureTech Health plc For: Dec 18 | SEC filing · Form 6-K | SEC EDGAR | — | +1.67% | |
| PureTech Appoints Robert Lyne as Chief Executive Officer | Press release | Business Wire | — | +1.67% | |
| Form 6-K PureTech Health plc For: Dec 10 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -0.06% | |
| PureTech Announces Successful End-of-Phase 2 Meeting with FDA for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis | Press release | Business Wire | — | -0.83% | |
| PureTech’s Founded Entity Gallop Oncology Announces Positive Initial Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome | Press release | Business Wire | +0.62% | +11.42% | |
| PureTech’s Founded Entity Gallop Oncology to Present New Data from Ongoing Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia (AML) at the American Society of Hematology (ASH) Annual Meeting | Press release | Business Wire | — | +1.89% | |
| PureTech Presents New Phase 2b Analyses Demonstrating Consistent Safety and Efficacy of Deupirfenidone in Older Patients with Idiopathic Pulmonary Fibrosis (IPF), a Historically Undertreated Group | Press release | Business Wire | — | -2.34% | |
| PureTech Presents New Data from Phase 2b Open-Label Extension Study of Deupirfenidone (LYT-100), Further Supporting Strong and Durable Efficacy and Potential to Serve as New Standard of Care in IPF | Press release | Business Wire | +0.00% | +3.12% | |
| PureTech Founded Entity Seaport Therapeutics Advances Second Therapeutic Candidate into Clinical Development with Dosing of First Participant in Phase 1 Study of GlyphAgo™ (SPT-320) in Healthy Volunteers | Press release | Business Wire | — | +2.58% | |
| Form 6-K PureTech Health plc For: Jun 30 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -0.86% | |
| PureTech Health plc – Half-Year Report | Press release | Business Wire | +0.00% | -0.86% | |
| PureTech Showcases Differentiated Development Strategy, Including New Patient Preference Insights, and Spotlights Phase 2b Data Positioning Deupirfenidone as a Potential New Standard of Care in IPF | Press release | Business Wire | — | +0.44% | |
| PureTech Health: Notice of Half-Yearly Results | Press release | Business Wire | — | +10.22% | |
| PureTech Founded Entity Vedanta Biosciences Announces Phase 2 Study of VE202 in Ulcerative Colitis Did Not Meet Primary Endpoint | Press release | Business Wire | +11.70% | +11.63% | |
| PureTech Announces the Launch of Celea Therapeutics With a Mission to Transform the Treatment of Respiratory Diseases | Press release | Business Wire | — | — | |
| PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2b BUOY-1 Study of GlyphAllo™ (SPT-300) in Major Depressive Disorder (MDD), With or Without Anxious Distress | Press release | Business Wire | +0.00% | -0.54% | |
| Form 6-K PureTech Health plc For: Jul 16 | SEC filing · Form 6-K | SEC EDGAR | — | +3.33% | |
| PureTech Announces Leadership Transition | Press release | Business Wire | — | +3.33% | |
| Form 6-K PureTech Health plc For: Jul 08 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | +4.04% | |
| PureTech Announces Board Change | Press release | Business Wire | — | +0.00% | |
| PureTech Founded Entity Vor Bio Announces Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset and $175 Million Private Placement | Press release | Business Wire | — | -0.88% | |
| Form 6-K PureTech Health plc For: Jun 16 | SEC filing · Form 6-K | SEC EDGAR | — | -6.34% | |
| PureTech Health: Results of Annual General Meeting | Press release | Business Wire | — | -0.26% | |
| PureTech to Present at the Jefferies Global Healthcare Conference | Press release | Business Wire | — | +4.97% | |
| PureTech’s Deupirfenidone (LYT-100) Demonstrates Strong and Durable Efficacy as a Monotherapy with Favorable Tolerability in Phase 2b ELEVATE IPF Trial | Press release | Business Wire | — | -3.19% | |
| PureTech Announces Publication of New Research Highlighting Untold Experiences of People Living with Idiopathic Pulmonary Fibrosis (IPF) | Press release | Business Wire | -7.67% | -2.49% | |
| PureTech to Present Results from Phase 2b ELEVATE IPF Trial of Deupirfenidone (LYT-100) at the American Thoracic Society International Conference | Press release | Business Wire | +0.00% | -0.17% | |
| Form 20-F PureTech Health plc For: Dec 31 | SEC filing · Form 20-F | SEC EDGAR | +0.00% | +3.80% | |
| Form 6-K PureTech Health plc For: Apr 30 | SEC filing · Form 6-K | SEC EDGAR | — | +0.17% | |
| PureTech Announces Annual Results for Year Ended December 31, 2024 | Press release | Business Wire | — | +0.17% | |
| PureTech Health: Notice of Results | Press release | Business Wire | +0.00% | -1.78% | |
| PureTech Appoints Peel Hunt as Joint UK Corporate Broker | Press release | Business Wire | — | +4.84% | |
| Form 6-K PureTech Health plc For: Apr 07 | SEC filing · Form 6-K | SEC EDGAR | — | -7.76% | |
| PureTech Health plc Statement Regarding Press Speculation | Press release | Business Wire | -0.20% | -13.50% | |
| PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair | Press release | Business Wire | — | — | |
| PureTech to Present at the Leerink Partners Global Healthcare Conference | Press release | Business Wire | — | -1.09% | |
| PureTech Founded Entity Seaport Therapeutics Announces the Publication of New Research Demonstrating Increased Lymphatic Transport with up to 55 Percent Drug Absorption via Lymphatics with GlyphTM Platform | Press release | Business Wire | — | +0.79% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the PRTC section they belong to.
Where else PRTC is measured.
PRTC earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is PureTech Health plc - American Depositary Shares's median reaction calculated?
Every labeled PRTC news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 385 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 45% of PRTC's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does PRTC's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.